Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevance Health, Inc. (NYSE: ELV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elevance Health operates in the direct health and medical insurance carriers industry and uses its SEC reports to present information on financial performance, capital structure, governance, and material events affecting its health benefits and Carelon segments.
Among the most important documents for ELV are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically include detailed discussions of segment results for Health Benefits and Carelon, membership metrics across commercial, Medicare, Medicaid, and Federal Employee Program lines, risk factors, and management’s analysis of trends in benefit expense ratios, operating expenses, and cash flows. They also describe Elevance Health’s role as a licensee of Blue Cross Blue Shield plans in multiple states and its activities in pharmacy and healthcare services through Carelon.
Elevance Health also files current reports on Form 8-K to disclose specific material events. Recent 8-Ks have covered quarterly earnings releases, reaffirmation of earnings guidance and benefit expense ratio expectations, the election of independent directors to the board and their committee assignments, and a multi-tranche notes offering with maturities extending to 2055. These filings provide insight into governance practices, capital markets activity, and management’s public communications with investors.
Investors interested in executive and board matters can review proxy-related filings and 8-K disclosures regarding director appointments and compensation programs for non-employee directors. Those analyzing Elevance Health’s capital structure can examine registration statements and debt-related exhibits referenced in 8-K filings, which describe terms of senior notes, redemption provisions, and events of default.
On Stock Titan, ELV filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and risk discussions, and help users quickly locate information on topics like Medicare and Medicaid program exposure, pharmacy and services operations under Carelon, and guidance-related forward-looking statements. Users can also review Form 4 insider transaction reports when available to monitor trading activity by Elevance Health directors and officers.
By using this filings page, investors and researchers can navigate Elevance Health’s regulatory history more efficiently, compare disclosures across reporting periods, and better understand how the company presents its health benefits and services business to regulators and the market.
Elevance Health EVP & Chief HR Officer Craig Ryan R reported multiple equity transactions. On March 2, 2026, he received an award of 11,754 employee stock options at an exercise price of $0.0000 per share, exercisable in three annual installments of 3,918 options beginning on March 2, 2027. He also acquired 2,976 shares of common stock as a grant, described as restricted share units with restrictions lapsing in three installments of 992 shares on March 2, 2027, March 2, 2028, and March 2, 2029. On March 2 and 3, 2026, a total of 334 common shares were disposed of at prices of $294.07 and $284.03 per share, respectively, as tax-withholding dispositions to cover liabilities upon vesting of previously granted restricted stock, rather than open‑market sales.
Elevance Health, Inc. executive Felicia F. Norwood reported equity compensation activity and related tax-withholding transactions. She received grants of 5,951 common shares and 2,865 performance-based restricted share units, plus an employee stock option covering 23,512 shares with future vesting installments.
To satisfy tax liabilities upon vesting of previously granted restricted stock, 496 common shares at $284.03 per share and 1,421 common shares at $294.07 per share were disposed of through stock withholding rather than open-market sales. Following these transactions, she directly owned 38,838 common shares.
Elevance Health EVP & Chief Digital Information Officer Ratnakar Lavu reported multiple equity compensation transactions. He received a grant of employee stock options covering 20,152 shares at an exercise price of $0.00 per share, exercisable in three installments beginning on 3/2/2027. He also acquired 5,101 and 6,802 shares that the footnotes describe as restricted share units with restrictions lapsing between 3/2/2027 and 3/2/2029. In separate transactions, 222 shares at $284.03 per share and 315 shares at $294.07 per share were withheld as common stock to satisfy tax liabilities on previously granted restricted stock vesting, rather than open-market sales.
Elevance Health EVP & President, Commercial, Kendrick Charles Morgan Jr. reported routine equity compensation changes. On March 2, 2026, he received 15,870 employee stock options exercisable in three equal annual installments starting on March 2, 2027, plus 6,549 common shares through restricted and performance-based stock unit awards. On March 2 and 3, 2026, a total of 1,678 common shares were disposed of at prices around $294.07 and $284.03, respectively, solely to cover tax liabilities upon vesting, leaving direct ownership of common stock.
Elevance Health EVP Peter D. Haytaian reported equity compensation activity in company common stock. On March 3, 2026, 446 shares were withheld at $284.03 per share, and on March 2, 2026, 1,201 shares were withheld at $294.07 per share to cover tax liabilities upon vesting of previously granted restricted stock. Also on March 2, he received a grant of 2,865 performance-based restricted share units as an award, bringing his directly held stake to 27,668 shares after these transactions.
Elevance Health EVP & CFO Mark Kaye reported multiple equity compensation transactions. He received grants of 6,377 and 10,202 restricted stock units, with restrictions scheduled to lapse between March 2, 2027 and March 2, 2029, and a stock option covering 25,188 shares exercisable in three annual installments beginning on March 2, 2027.
To cover tax liabilities tied to previously granted restricted stock vesting, he disposed of 353 and 271 common shares at prices of $284.03 and $294.07 per share through share withholding, rather than open-market sales.
Elevance Health President and CEO Gail Boudreaux reported a mix of equity grants and tax-related share dispositions. She received a grant of 63,818 employee stock options exercisable in three annual installments beginning on 3/2/2027. She was also awarded 16,153 and 10,527 common shares as restricted share unit and performance-based restricted share unit grants. To cover tax liabilities upon vesting of previously granted restricted stock, 1,736 common shares at $284.03 per share and 6,713 shares at $294.07 per share were withheld. After these transactions, she held 169,251 common shares directly, and 60 additional shares were reported as held indirectly in her spouse's revocable trust.
Elevance Health disclosed that the Centers for Medicare & Medicaid Services plans to impose intermediate sanctions on its Medicare Advantage-Prescription Drug plans. The sanctions would suspend new Medicare beneficiary enrollment and certain communications starting March 31, 2026, if CMS is not satisfied that identified issues are resolved.
CMS indicated the proposed sanctions relate to alleged noncompliance with Medicare Advantage risk adjustment data submission requirements for services before April 3, 2023. Elevance Health states that it revised its practices in April 2023 after additional regulatory guidance and is working cooperatively with CMS. The suspension does not affect current members’ existing benefits or plans.
Elevance Health announced management changes and reaffirmed its 2026 financial outlook. Executive Vice President and Carelon President Peter D. Haytaian will leave his Carelon role effective May 4, 2026 to focus on family, and will serve as Special Advisor through December 31, 2026 to support a smooth transition.
Chief Financial Officer Mark Kaye will add oversight of Carelon, the company’s healthcare services operations, while Felicia Norwood will lead a consolidated Health Benefits organization under a single accountable structure. Elevance Health reaffirmed full-year 2026 shareholders’ earnings guidance of at least $22.30 per diluted share, including about $3.20 of net unfavorable items, and at least $25.50 per diluted share on an adjusted basis. The company also reaffirmed its 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points.
Elevance Health is one of the largest U.S. health insurers, serving about 45.2 million medical members as of December 31, 2025. It operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other.
The company offers commercial, Medicare, Medicaid, federal employee and specialty plans, and earns revenue from risk-based premiums, self‑funded administrative fees, and pharmacy and health service fees. About 32% of consolidated revenue in 2025 came from U.S. government agencies. Elevance leverages Blue Cross and Blue Shield licenses in multiple states, value‑based provider contracts, and digital tools such as its Sydney Health platform to manage costs and quality.
CarelonRx provides pharmacy benefit management and infusion services, while Carelon Services integrates physical, behavioral, pharmacy and social‑care capabilities. The 10‑K highlights extensive regulation under the ACA, the IRA, Medicaid redeterminations, transparency and privacy rules, and notes that results depend heavily on medical cost trends, membership mix and CMS Star Ratings. The company reports a global workforce of roughly 97,100 employees and emphasizes culture, inclusion and fair pay.